Translate Register Log In Login with facebookLogin and Register

3 weeks of Vitamin D can not help much (Breast Cancer surgery in this case) – RCT Aug 2019

Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients.

Breast Cancer Res Treat. 2019 Aug 9. doi: 10.1007/s10549-019-05392-9.


The body probably only had a few days to make use of a good level of vitamin D (reached 94 ng)
A loading dose (get all of the vitamin D in 1-7 days) would get a similar level in 1 week.
But it is doubtful than the extra week would help much

Overview Breast Cancer and Vitamin D contains the following

Arnaout A1,2, Robertson S3, Pond GR4, Vieth R5, Jeong A2, Hilton J2,6, Ramsey T7, Clemons M8,9.
1 Division of Surgical Oncology, Department of Surgery, Ottawa Hospital, Ottawa, Canada.
2 Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
3 Division of Anatomical Pathology, Ottawa Hospital, Ottawa, Canada.
4 Department of Oncology, McMaster University, Hamilton, Canada.
5 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
6 Division of Medical Oncology, Department of Medicine, University of Ottawa and Ottawa Hospital Cancer Center, Ottawa, ON, Canada.
7 Center for Practice Changing Research, Ottawa Hospital Research Institute, Ottawa, Canada.
8 Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada. mclemons at toh.ca.
9 Division of Medical Oncology, Department of Medicine, U. of Ottawa and Ottawa Hospital Cancer Center, Ottawa, mclemons at toh.ca.

Epidemiologic and preclinical data suggest a potential role for vitamin D in breast cancer treatment and prevention. However, results of prospective randomized trials are inconsistent. The objective of this study was to assess the effects of high-dose cholecalciferol (vitamin D3) on breast tumour proliferation and apoptosis.

We conducted a prospective, randomized, phase 2, double-blinded pre-surgical window of opportunity trial. Newly diagnosed breast cancer patients were randomized to receive 40,000 IU of vitamin D3 per day or placebo for 2 to 6 weeks prior to breast surgery. The primary outcome was the relative change in proliferation (Ki67) and apoptosis (cleaved caspase 3 apoptotic assay [CC3]) in primary breast cancer cells pre and post treatment.

Of 83 patients randomized, 80 completed the study (43 (53.8%) vitamin D and 37 (46.3%) placebo). Mean duration of drug intake was 19 days (range 9-28 days). There were no significant differences between the control arm and the vitamin D arm in percent changes of either Ki67 index (1.6% vs. 16.7%, p = 0.25) or CC3 (- 55.9% vs. - 45.9%, p = 0.28). Serum 25-hydroxyvitamin D (25-OHD) levels were 3 times higher in the vitamin D arm (62 nmol/L vs. 246 nmol/L, p < 0.001). Adverse effects were minimal and all classified as grade 1.

Despite significantly higher levels of serum 25-OHD in the vitamin D-treated group, this was not associated with any significant effects on tumour proliferation or apoptosis. These findings are consistent with the lack of benefit observed in prospective prevention trials.

Created by admin. Last Modification: Sunday August 11, 2019 18:33:45 GMT-0000 by admin. (Version 4)
See any problem with this page? Report it (FINALLY WORKS)